5-hydroxytryptamine receptor 2C
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 5-hydroxytryptamine receptor 2C as ChEMBL target CHEMBL324, mapped to UniProt P08909. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why 5-hydroxytryptamine receptor 2C matters
5-hydroxytryptamine receptor 2C is reviewed as 5-hydroxytryptamine receptor 2C (UniProt P08909); the current evidence base includes 14 approved drugs, 908 compounds, and 146 assays, with lead potency reaching pChEMBL 10.0.
5-hydroxytryptamine receptor 2C Sequence length is 460 aa.
Review this target as 5-hydroxytryptamine receptor 2C, mapped to UniProt P08909. Sequence length is 460 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 14 approved drugs, 908 compounds, and 146 assays for this target. The dominant activity type is KI. CHEMBL6706 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL6706 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 2C matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P08909, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL6706
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL3764539
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL111184
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL14563
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL324270
|
9.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
MIRTAZAPINE
CHEMBL654
|
1996 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
BUSPIRONE
CHEMBL49
|
1986 |
|
|
LOXAPINE
CHEMBL831
|
1975 |
|
|
MIANSERIN
CHEMBL6437
|
— |